Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Sun, W.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Leist, S.R.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • McCroskery, S.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Liu, Y.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Slamanig, S.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Oliva, J.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Amanat, F.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Schäfer, A.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Dinnon, III, K.H.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • García-Sastre, A.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Krammer, F.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Baric, R.S.
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
  • Palese, P.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
Abstract
  • Background: Due to the lack of protective immunity of humans towards the newly emerged SARS-CoV-2, this virus has caused a massive pandemic across the world resulting in hundreds of thousands of deaths. Thus, a vaccine is urgently needed to contain the spread of the virus. Methods: Here, we describe Newcastle disease virus (NDV) vector vaccines expressing the spike protein of SARS-CoV-2 in its wild type format or a membrane-anchored format lacking the polybasic cleavage site. All described NDV vector vaccines grow to high titers in embryonated chicken eggs. In a proof of principle mouse study, the immunogenicity and protective efficacy of these NDV-based vaccines were investigated. Findings: We report that the NDV vector vaccines elicit high levels of antibodies that are neutralizing when the vaccine is given intramuscularly in mice. Importantly, these COVID-19 vaccine candidates protect mice from a mouse-adapted SARS-CoV-2 challenge with no detectable viral titer and viral antigen in the lungs. Interpretation: The results suggested that the NDV vector expressing either the wild type S or membrane-anchored S without the polybasic cleavage site could be used as live vector vaccine against SARS-CoV-2. Funding: This work is supported by an NIAID funded Center of Excellence for Influenza Research and Surveillance (CEIRS) contract, the Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract, philanthropic donations and NIH grants.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution-NonCommercial-NoDerivs 3.0 United States
Journal title
  • EBioMedicine
Journal volume
  • 62
Language
  • English
Version
  • Publisher
ISSN
  • 2352-3964
Publisher
  • Elsevier B.V.

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 1-s2.0-S2352396420305089-main.pdf 2021-01-04 Public Download